SUMMARY Short stature is a common complication of inflammatory bowel disease. Recently McCaffery, Nasr, Lawrence, and Kirsner (1970) concluded, from blood growth hormone (GH) levels obtained during insulin-hypoglycaemic provocation, that GH deficiency contributed to the retardation in growth observed in subjects with inflammatory bowel disease. Although it was not possible to eliminate the possibility of partial hypopituitarism, this study does not confirm the existence of GH deficiency in six subjects with short stature complicating inflammatory bowel disease. The nyctohemeral (night and day) serum GH is described, and the insulin and glucose levels in these subjects and normal sleep-related GH rises in all are demonstrated. This finding is not compatible with growth hormone deficiency. In one subject the response to arginine provocation was blunted. Three subjects manifested hyperinsulinism and evidence for 'insulin resistance'. These findings are unexplained but suggest that insulin resistance may contribute to a blunted GH response to insulin-induced hypoglycaemia. Blunted GH response to both arginine and insulin-induced hypoglycaemia may also result from continuous secretion and reduced pituitary storage of growth hormone. This possibility is suggested by the pattern of raised blood GH levels in one of the subjects.
Retarded growth is a common clinical feature observed in children with inflammatory bowel disease. The pathogenic mechanisms contributing to the failure of growth in these subjects has not been elucidated but it is probably not secondary to endocrine deficiency (Sobel, 1969) . Possible causes include caloric deficiency resulting from anorexia or malabsorption and 'end-organ subresponsiveness' in peripheral tissues to adequate serum levels of growth-promoting hormones. Recently McCaffery and his colleagues reported diminished blood growth hormone (GH) levels in 11 children with inflammatory bowel disease and suggested that an endocrine deficiency state resulting from hypopituitarism might be the cause of their short stature (McCaffery et al, 1970 ). This conclusion was based on subnormal rises in growth hormone observed in response to a conventional growth hormone provocation test, viz, insulin hypoglycaemia.
The recognition that growth hormone rises physiologically during normal sleep (Takahashi, Kipnis, and Daughaday, 1968) to levels comparable in magnitude and longer in duration than rises observed with conventional provocation tests has made possible a more definitive test of growth hormone secretion (Mace, Gotlin, Sassin, Parker, and Rossman, 1970; Mace, Gotlin, and Beck, 1972) . Since marked discrepancies between physiological sleep-related rises of growth hormone and those observed with conventional provocation have been reported , we evaluated further the possibility raised by McCaffery and his coworkers that the retarded growth observed in children with inflammatory bowel disease is the result of growth hormone deficiency. The nyctohemeral (night and day) blood levels of growth hormone, insulin, and glucose were studied in six subjects with inflammatory bowel disease and severe growth retardation. In addition the growth hormone levels in response to arginine provocation were compared with rises occurring during natural sleep. The results reported here failed to support the conclusion that a growth hormone deficiency state exists in these subjects with inflammatory bowel disease.
Materials and Methods
Six patients whose ages ranged from 12 years 3 months to 14 years 9 months were studied (table I) The growth hormone and insulin determinations were performed by double antibody radioimmunoassay, growth hormone by the method of Schlach and Parker (1964) , insulin by the method of Morgan and Lazarow (1963) . Glucose was determined by the glucose oxidase method (Marks, 1959) , cortisol by the fluorescent method of Clark and Rubin (1969) , T4 by column chromatography (Pileggi and Kessler, 1968) , 17-ketosteroids by the method of Norymberski (Sobel, Golub, Henry, Jacobs, and Basu, 1958) , 17-ketogenic steroids by the Zimmerman reaction (Birke, Diczfalusy, and Plaitin, 1958) , and pituitary gonadotrophins by bioassay (Bioscience Laboratories, California).
Results

GROWTH HIORMONE ANALYSIS
In (9.6-18) Table I Growth hormone levels in normal subjects and subjects with inflammatory bowel disease 'Receiving prednisone 5 mg bid at time of study related GH rises (> 7 ng/ml) (Mace et al, 1970 (Mace et al, , 1972 . Although the range and mean GH levels for the entire nyctohemeral period were slightly elevated in subject 4, the difference was not statistically significant from controls. The GH response to arginine infusion in control subjects and subjects with gastrointestinal disease was comparable (> 9 ng/ml taken as the lowest acceptable GH rise in normal subjects) although in subject 6 the baseline level is raised and the response to arginine is blunted.
NYCTOHEMERAL INSULIN AND GLUCOSE LEVELS
The pattern of blood insulins (Table II) showed appropriate rises in response to meals and arginine in all subjects and remained low (<20 mU/ml) throughout the nocturnal period in all subjects except cases 3 and 4. (In subject 5, sporadic hyperinsulinaemia in relation to meals was observed.) In these subjects elevated nocturnal levels were observed and were abnormal when compared with the normal controls (p < 0-05). The subject receiving prednisone did not have raised nocturnal insulin levels.
The glucose levels in all subjects were normal and varied appropriately with meals. Hypoglycaemia did not occur in the subjects with elevated insulin levels but the insulin: glucose ratios were abnormally elevated.
THYROID, GONAD, AND ADRENAL FUNCTION
T4 determinations and 24-hour urinary gonadotrophin and steroid levels were in the normal range in all subjects. With the exception of case 1, a normal diurnal variation in cortisol was observed. Therefore, although specific or indirect tests of the pituitary-thyroid, pituitary-gonad, and pituitaryadrenal axes were not performed, there was no laboratory evidence of secondary thyroid, gonadal, or adrenal insufficiency.
Discussion and Conclusions
We have investigated in six subjects with inflammatory bowel disease and severe growth retardation the possibility that deficiency of growth hormone contributes to the retardation in growth frequently observed in these diseases. The results ofthis study are not in keeping with GH deficiency. Moreover, we did not detect evidence for pituitary-thyroid, pituitary-gonad, or pituitary-adrenal insufficiency.
In a recent report by McCaffery and colleagues it was suggested that the growth retardation commonly associated with inflammatory bowel disease was secondary to hypopituitarism (McCaffery et al, 1970) . We have no explanation for the disparity between our results and those reported by McCaffery and associates. Since different methods were employed in assessing growth hormone secretion, the two studies are not entirely comparable.
The blood growth hormone rise observed during natural sleep is a physiological phenomenon which may be altered if deep sleep is delayed or interrupted (Sassin, Parker, Mace, Gotlin, Johnson, and Rossman, 1969 ). In patients with inflammatory bowel disease, we anticipated that sleep might be disturbed by abdominal discomfort as well as anxiety. In subject 2 of this study, abdominal pain was present throughout the study night interfering with both the onset and continuity of sleep. It is of interest that the blood GH pattern during this period did not show a GH rise until early morning (0400 hours). In normal subjects, sleep-related GH rises usually occur in association with slow wave 27-0 ± 17-1 98-0 ± 13-1 5-108 56-148 18-0 26.5 89-0 i 41 5-37 79-102 26-0 ± 8-6 84-0 ± 6-7 740 ± 12.0 106-0 9-2 (Takahashi et al, 1968; Parker et al, 1969) .
We have previously observed discrepancies in the same subjects between blood GH rises occurring during sleep and rises observed in response to conventional growth hormone-provoking agents . The absence of blood GH rise in response to insulin hypoglycaemia observed by McCaffery and coworkers is therefore not diagnostic of GH deficiency.
Two additional observations of this study deserve comment. Subject 4 manifested nyctohemeral elevations in blood growth hormone. This is a finding previously observed in subjects with acromegaly , anorexia nervosa (unpublished observation), primordial short stature (Gotlin, Mace, and Silver, 1971) , and subjects with other types of gastroenteropathy . Raised nyctohemeral blood GH levels suggest that the hormone is biologically inactive or that the peripheral tissue ('end-organ') is subresponsive. The latter seems more likely and may result from caloric deficiency or other alterations in the internal environment in chronic diseases such as inflammatory bowel disease or chronic renal disease (Simmons, Wilson, Potter, and Holliday, 1971) .
Previous reports of elevated 'basal' GH levels and diminished responsiveness to arginine and insulinhypoglycaemic provocation, as observed in our sixth subject, have been reported (Frohman, Aceto, and MacGillivray, 1967; Youlton, Kaplan, and Grumbach, 1969) . From examination of the data reported by McCaffery and associates, it seems possible that the diminished GH response to insulin hypoglycaemia in some of their subjects may have resulted from elevated nyctohemeral GH secretion and depleted pituitary GH stores.
In subjects 3, 4, and 5 elevated blood insulin levels were observed throughout the 24-hour study interval. This finding has been observed previously in subjects with acromegaly (Elkeles, Wright, Lowy, and Fraser, 1969) and exogenous obesity (Gotlin, MacReynolds, and Dubois, 1971 ), and we have observed hyperinsulinism in other subjects with gastrointestinal disease Puberty was abnormal in onset and progression in each of our subjects and abnormalities of puberty are common in chronic systemic diseases. The combination of short stature, retarded skeletal maturation, and the deficient caloric intake of gastrointestinal disease states may be of importance in explaining the delayed puberty in our subjects as well as in subjects with other types of chronic disease. Since the timing of onset and progression of puberty may well be controlled by a 'critical weight' (Frisch, 1972) , it seems likely that the abnormalities ofpuberty are a feature of the poor nutritional status of our subjects.
The observed abnormalities of puberty could also be the result of partial hypopituitarism as proposed by McCaffery and coworkers (1970) . Since urinary pituitary gonadotrophin levels were not abnormal, our data do not support a hypothalamic-pituitary deficiency or abnormality. Nonetheless, the urinary bioassay of gonadotrophin is a crude assessment of hypothalamic pituitary function and our data do not exclude a partial deficiency or a subtle abnormality in the timing, or in the FSH/LH ratio in these patients. Extensive longitudinal studies, such as are described here for GH, employing sensitive radioimmunoassay techniques for FSH and LH, will be helpful in elucidating these possibilities.
